The blood test is a first-line screen to identify patients who may need more invasive and expensive follow-ups like PET scans or CSF tests. This minimizes unnecessary procedures for those at low risk, optimizing the diagnostic pathway and improving patient experience.
Developing a blood test for a condition like Alzheimer's is complex because biomarkers like amyloid proteins can also be expressed due to other conditions, such as cardiovascular disease. This requires extensive population studies to understand confounding factors and ensure test accuracy.
Fujirebio's transition from oncology to neurodegenerative diseases was not built from scratch. It was accelerated by acquiring Innogenetics, a Belgian company that had already spent two decades researching Alzheimer's biomarkers. This "buy vs. build" strategy enabled a rapid and expert entry into a new therapeutic area.
The biological markers for Alzheimer's, such as amyloid protein clumps, can appear 10 to 20 years before cognitive symptoms manifest. This extensive preclinical phase makes early, non-invasive blood tests critical for identifying patients when new treatments that slow disease progression are most effective.
The biomarkers and diagnostic platform developed for Alzheimer's are not a one-off success. Fujirebio is now investigating the application of these same biomarkers for other neurodegenerative diseases like MS and Parkinson's, effectively turning a single product's technology into a broader R&D pipeline.
For decades, Fujirebio's technology was embedded as a white-label component in other companies' diagnostic products. Receiving a public award put their own name on the map, serving as a powerful external validation and internal morale booster that recognized their direct contribution to innovation.